Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process.</li><li> The company released its 2Q financial report that showed improved good cash balances and bested estimates.</li><li>The company continues along two courses of business that we believe have excellent prospects.</li></ul>

Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process. The company released its 2Q financial report that showed improved good cash balances and bested estimates.The company continues along two courses of business that we believe have excellent prospects.

ONVO:  Quarterly Results Exceed Forecasts

<ul><li>Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process.</li><li> The company released its 1Q financial report that showed improved good cash balances and bested estimates.</li><li>The company also recently reiterated positive Phase 2 results for one of its primary treatments-FXR314.</li></ul>

Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process. The company released its 1Q financial report that showed improved good cash balances and bested estimates.The company also recently reiterated positive Phase 2 results for one of its primary treatments-FXR314.

ONVO:  Test Results Could Open Door to Acquisition

<ul><li>Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process.</li><li> The company released its annual report that showed good cash balances, and also recently released positive Phase 2 results for one of its primary treatments-FXR314.</li><li>These results are very encouraging and bolster our belief in the future prospects for ONVO.</li></ul>

Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process. The company released its annual report that showed good cash balances, and also recently released positive Phase 2 results for one of its primary treatments-FXR314.These results are very encouraging and bolster our belief in the future prospects for ONVO.

ONVO:  Annual Report Bolsters Case for Company

<ul><li>Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process.</li><li> The company recently released positive Phase 2 results for one of its primary treatments-FXR314.</li><li>These results are very encouraging and bolsters our belief in the future prospects for ONVO. </li></ul>

Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target diseases and accelerate the drug development process. The company recently released positive Phase 2 results for one of its primary treatments-FXR314.These results are very encouraging and bolsters our belief in the future prospects for ONVO. 

ONVO:  Positive Phase 2 Results Bolsters Outlook

United States

Organovo Holdings, Inc. operates as a biology company. The Company focuses on bio-printing technology and creating tissues for research and medical applications.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Organovo Holdings (ONVO US)

ONVO: Quarterly Results Exceed Forecasts

Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target...

Zacks Small Cap Research

ONVO: Test Results Could Open Door to Acquisition

Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target...

Zacks Small Cap Research

ONVO: Annual Report Bolsters Case for Company

Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target...

Zacks Small Cap Research

ONVO: Positive Phase 2 Results Bolsters Outlook

Organovo is a biotech company that has 3D technology enabling the company to produce various human tissues, allowing the company to target...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)